293 related articles for article (PubMed ID: 27414976)
1. Platelet function testing as a biomarker for efficacy of antiplatelet drugs.
Lordkipanidzé M; So D; Tanguay JF
Biomark Med; 2016 Aug; 10(8):903-18. PubMed ID: 27414976
[TBL] [Abstract][Full Text] [Related]
2. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Bernlochner I; Byrne RA; Kastrati A; Sibbing D
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
[TBL] [Abstract][Full Text] [Related]
3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
4. Platelet Function Testing in Patients on Antiplatelet Medications.
Gross L; Aradi D; Sibbing D
Semin Thromb Hemost; 2016 Apr; 42(3):306-20. PubMed ID: 26886395
[TBL] [Abstract][Full Text] [Related]
5. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
6. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675
[TBL] [Abstract][Full Text] [Related]
7. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
8. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
[TBL] [Abstract][Full Text] [Related]
9. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
10. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Antiplatelet Therapy.
Orme R; Judge HM; Storey RF
Semin Thromb Hemost; 2017 Apr; 43(3):311-319. PubMed ID: 28264200
[TBL] [Abstract][Full Text] [Related]
12. Advances in the monitoring of anti-P2Y12 therapy.
Harrison P
Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
[TBL] [Abstract][Full Text] [Related]
13. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
15. Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
Steiner S; Moertl D
Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):975-84. PubMed ID: 23984925
[TBL] [Abstract][Full Text] [Related]
16. High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values.
Leunissen TC; Peeters Weem SM; Urbanus RT; den Ruijter HM; Moll FL; Asselbergs FW; de Borst GJ
Eur J Vasc Endovasc Surg; 2016 Aug; 52(2):198-204. PubMed ID: 27236738
[TBL] [Abstract][Full Text] [Related]
17. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
[TBL] [Abstract][Full Text] [Related]
18. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
19. Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors.
Howell LA; Stouffer GA; Polasek M; Rossi JS
Expert Rev Clin Pharmacol; 2015; 8(4):411-21. PubMed ID: 26092217
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
